Nacolomab

Nacolomab is a monoclonal antibody for the treatment of cancer. This drug was developed by Neoprobe Corporation.

History[edit | edit source]

Nacolomab was originally developed by Neoprobe Corporation, a biopharmaceutical company specializing in the development of oncology and cardiovascular surgical and diagnostic products. The drug is a monoclonal antibody, a type of protein made in the laboratory that can bind to substances in the body, including cancer cells.

Mechanism of Action[edit | edit source]

As a monoclonal antibody, Nacolomab works by targeting and binding to specific cells or proteins, which stimulates the body's immune system to attack those cells. This is a common mechanism of action for many cancer treatments, as it allows for targeted therapy that can minimize damage to healthy cells.

Clinical Trials[edit | edit source]

Nacolomab has undergone various clinical trials to assess its safety and efficacy in treating cancer. These trials are crucial steps in the drug development process, as they provide the data necessary for regulatory approval.

Side Effects[edit | edit source]

Like all drugs, Nacolomab can cause side effects. The nature and severity of these side effects can vary widely and are often dependent on the dosage and duration of treatment.

See Also[edit | edit source]

Nacolomab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.